Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05742750
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-02-24
First Post:
2023-02-15
Brief Title:
A Phase IbII Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Camrelizumab Combined With Apatinib and Gemcitabine Plus Cisplatin as First-line Therapy for Patients With InoperableMetastatic Biliary Tract Cancer BTC An Open-label Single-arm Single-center Phase IbII Clinical Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to investigate the safety and tolerability of camrelizumab combined with apatinib and chemotherapies gemcitabine and cisplatin in patients with advanced biliary tract cancer BTC
Detailed Description:
The study consists of 2 parts a dose-escalation part Phase 1 and an expansion part Phase 2 Both parts will enroll participants with advanced unresectable biliary tract cancer that had not previously treated with systemic therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None